Targeting tumour vasculature: the development of combretastatin A4
The requirement for neovascularisation to permit the development of solid tumours beyond a threshold size, has focused attention on the therapeutic potential of agents that prevent angiogenesis. The multistep nature of angiogenesis presents several targets for intervention, including the inhibition...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2001-02, Vol.2 (2), p.82-87 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 87 |
|---|---|
| container_issue | 2 |
| container_start_page | 82 |
| container_title | The lancet oncology |
| container_volume | 2 |
| creator | Griggs, Jeremy Metcalfe, James C Hesketh, Robin |
| description | The requirement for neovascularisation to permit the development of solid tumours beyond a threshold size, has focused attention on the therapeutic potential of agents that prevent angiogenesis. The multistep nature of angiogenesis presents several targets for intervention, including the inhibition of the endothelial-cell migration or proliferation normally associated with developing vessels. Compounds that damage established tumour vasculature are also of potential clinical use. We review the development of one such antivascular drug, combretastatin A4. This tubulin-binding agent was originally isolated from an African shrub,
Combretum caffrum. The disodium combretastatin A4 phosphate prodrug is currently undergoing phase I clinical trials in the UK and USA. This review assesses the
in vitro and
in vivo data for combretastatin and the prodrug, and the preliminary data that have emerged from the phase I clinical trials. |
| doi_str_mv | 10.1016/S1470-2045(00)00224-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71289418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204500002242</els_id><sourcerecordid>71289418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-dedeec81fa919320db7a26e5db6ac5b33feed53189b3fb7e974090c86a286ab93</originalsourceid><addsrcrecordid>eNqFkMtKxTAQhoMo3h9BKS5EF9VJmraJG9GDNzjgQl2HNJlqpZdjkh7w7c25gODGRZgQvn8m8xFyROGCAi0uXygvIWXA8zOAcwDGeMo2yG585mnOhdhc3lfIDtnz_hOAlhTybbJDqYS8lHKX3L5q946h6d-TMHbD6JK59mZsdRgdXiXhAxOLc2yHWYd9SIY6MUNXOQzaBx1jyQ0_IFu1bj0erus-ebu_e508ptPnh6fJzTQ1mRAhtWgRjaC1llRmDGxValZgbqtCm7zKshrR5hkVssrqqkRZcpBgRKFZPJXM9snpqu_MDV8j-qC6xhtsW93jMHpVUiYkpyKCJ3_Az7hYH_-mGNBoAQoeoXwFGTd477BWM9d02n0rCmphWC0Nq4U-BaCWhhWLueN187Hq0P6m1kojcL0CMLqYN-iUNw32Bm3j0ARlh-afET8Ecoqs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201001064</pqid></control><display><type>article</type><title>Targeting tumour vasculature: the development of combretastatin A4</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Griggs, Jeremy ; Metcalfe, James C ; Hesketh, Robin</creator><creatorcontrib>Griggs, Jeremy ; Metcalfe, James C ; Hesketh, Robin</creatorcontrib><description>The requirement for neovascularisation to permit the development of solid tumours beyond a threshold size, has focused attention on the therapeutic potential of agents that prevent angiogenesis. The multistep nature of angiogenesis presents several targets for intervention, including the inhibition of the endothelial-cell migration or proliferation normally associated with developing vessels. Compounds that damage established tumour vasculature are also of potential clinical use. We review the development of one such antivascular drug, combretastatin A4. This tubulin-binding agent was originally isolated from an African shrub,
Combretum caffrum. The disodium combretastatin A4 phosphate prodrug is currently undergoing phase I clinical trials in the UK and USA. This review assesses the
in vitro and
in vivo data for combretastatin and the prodrug, and the preliminary data that have emerged from the phase I clinical trials.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(00)00224-2</identifier><identifier>PMID: 11905799</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Angiogenesis ; Antineoplastic Agents, Phytogenic - therapeutic use ; Blood vessels ; Cell adhesion & migration ; Cells, Cultured ; Clinical trials ; Clinical Trials as Topic ; Cytotoxicity ; Extracellular matrix ; Humans ; Neoplasms - blood supply ; Neoplasms - drug therapy ; Stilbenes - therapeutic use ; Tumors ; Vascular endothelial growth factor</subject><ispartof>The lancet oncology, 2001-02, Vol.2 (2), p.82-87</ispartof><rights>2001 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Feb 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-dedeec81fa919320db7a26e5db6ac5b33feed53189b3fb7e974090c86a286ab93</citedby><cites>FETCH-LOGICAL-c388t-dedeec81fa919320db7a26e5db6ac5b33feed53189b3fb7e974090c86a286ab93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/201001064?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982,64370,64372,64374,72224</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11905799$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Griggs, Jeremy</creatorcontrib><creatorcontrib>Metcalfe, James C</creatorcontrib><creatorcontrib>Hesketh, Robin</creatorcontrib><title>Targeting tumour vasculature: the development of combretastatin A4</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>The requirement for neovascularisation to permit the development of solid tumours beyond a threshold size, has focused attention on the therapeutic potential of agents that prevent angiogenesis. The multistep nature of angiogenesis presents several targets for intervention, including the inhibition of the endothelial-cell migration or proliferation normally associated with developing vessels. Compounds that damage established tumour vasculature are also of potential clinical use. We review the development of one such antivascular drug, combretastatin A4. This tubulin-binding agent was originally isolated from an African shrub,
Combretum caffrum. The disodium combretastatin A4 phosphate prodrug is currently undergoing phase I clinical trials in the UK and USA. This review assesses the
in vitro and
in vivo data for combretastatin and the prodrug, and the preliminary data that have emerged from the phase I clinical trials.</description><subject>Angiogenesis</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Blood vessels</subject><subject>Cell adhesion & migration</subject><subject>Cells, Cultured</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Cytotoxicity</subject><subject>Extracellular matrix</subject><subject>Humans</subject><subject>Neoplasms - blood supply</subject><subject>Neoplasms - drug therapy</subject><subject>Stilbenes - therapeutic use</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkMtKxTAQhoMo3h9BKS5EF9VJmraJG9GDNzjgQl2HNJlqpZdjkh7w7c25gODGRZgQvn8m8xFyROGCAi0uXygvIWXA8zOAcwDGeMo2yG585mnOhdhc3lfIDtnz_hOAlhTybbJDqYS8lHKX3L5q946h6d-TMHbD6JK59mZsdRgdXiXhAxOLc2yHWYd9SIY6MUNXOQzaBx1jyQ0_IFu1bj0erus-ebu_e508ptPnh6fJzTQ1mRAhtWgRjaC1llRmDGxValZgbqtCm7zKshrR5hkVssrqqkRZcpBgRKFZPJXM9snpqu_MDV8j-qC6xhtsW93jMHpVUiYkpyKCJ3_Az7hYH_-mGNBoAQoeoXwFGTd477BWM9d02n0rCmphWC0Nq4U-BaCWhhWLueN187Hq0P6m1kojcL0CMLqYN-iUNw32Bm3j0ARlh-afET8Ecoqs</recordid><startdate>20010201</startdate><enddate>20010201</enddate><creator>Griggs, Jeremy</creator><creator>Metcalfe, James C</creator><creator>Hesketh, Robin</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20010201</creationdate><title>Targeting tumour vasculature: the development of combretastatin A4</title><author>Griggs, Jeremy ; Metcalfe, James C ; Hesketh, Robin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-dedeec81fa919320db7a26e5db6ac5b33feed53189b3fb7e974090c86a286ab93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Angiogenesis</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Blood vessels</topic><topic>Cell adhesion & migration</topic><topic>Cells, Cultured</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Cytotoxicity</topic><topic>Extracellular matrix</topic><topic>Humans</topic><topic>Neoplasms - blood supply</topic><topic>Neoplasms - drug therapy</topic><topic>Stilbenes - therapeutic use</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Griggs, Jeremy</creatorcontrib><creatorcontrib>Metcalfe, James C</creatorcontrib><creatorcontrib>Hesketh, Robin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Griggs, Jeremy</au><au>Metcalfe, James C</au><au>Hesketh, Robin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting tumour vasculature: the development of combretastatin A4</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2001-02-01</date><risdate>2001</risdate><volume>2</volume><issue>2</issue><spage>82</spage><epage>87</epage><pages>82-87</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><abstract>The requirement for neovascularisation to permit the development of solid tumours beyond a threshold size, has focused attention on the therapeutic potential of agents that prevent angiogenesis. The multistep nature of angiogenesis presents several targets for intervention, including the inhibition of the endothelial-cell migration or proliferation normally associated with developing vessels. Compounds that damage established tumour vasculature are also of potential clinical use. We review the development of one such antivascular drug, combretastatin A4. This tubulin-binding agent was originally isolated from an African shrub,
Combretum caffrum. The disodium combretastatin A4 phosphate prodrug is currently undergoing phase I clinical trials in the UK and USA. This review assesses the
in vitro and
in vivo data for combretastatin and the prodrug, and the preliminary data that have emerged from the phase I clinical trials.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>11905799</pmid><doi>10.1016/S1470-2045(00)00224-2</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2001-02, Vol.2 (2), p.82-87 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71289418 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Angiogenesis Antineoplastic Agents, Phytogenic - therapeutic use Blood vessels Cell adhesion & migration Cells, Cultured Clinical trials Clinical Trials as Topic Cytotoxicity Extracellular matrix Humans Neoplasms - blood supply Neoplasms - drug therapy Stilbenes - therapeutic use Tumors Vascular endothelial growth factor |
| title | Targeting tumour vasculature: the development of combretastatin A4 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T21%3A45%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20tumour%20vasculature:%20the%20development%20of%20combretastatin%20A4&rft.jtitle=The%20lancet%20oncology&rft.au=Griggs,%20Jeremy&rft.date=2001-02-01&rft.volume=2&rft.issue=2&rft.spage=82&rft.epage=87&rft.pages=82-87&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(00)00224-2&rft_dat=%3Cproquest_cross%3E71289418%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201001064&rft_id=info:pmid/11905799&rft_els_id=S1470204500002242&rfr_iscdi=true |